US-based LiviWell has closed a $3.3 million oversubscribed seed funding round to complete FDA clearance and launch Livi, a medical device designed to absorb semen and maintain vaginal pH balance after intercourse.
The round was led by Atlantic Venture Studio, a subsidiary of Atlantic Health System. The company submitted Livi for FDA clearance in June 2025.
Livi is a medical-grade polyurethane foam device inserted vaginally via applicator immediately after intercourse. The product absorbs semen and post-coital fluids in under 60 seconds, aiming to prevent pH imbalances that can lead to bacterial vaginosis, odor, and discharge.
“This funding represents more than capital—it’s a validation of our team’s dedication and the potential impact Livi can have on women’s sexual health and quality of life,” said Dawn Halkuff, CEO of LiviWell. “With this support, we’re positioned to navigate the FDA clearance process and bring Livi to the women who need it most.”
The device has undergone clinical trials led by women’s pelvic health physicians, though specific trial results and participant numbers were not disclosed. Upon FDA clearance, Livi would be the first authorized product specifically for post-intercourse vaginal care, according to the company.
The product targets common post-coital symptoms that affect millions of sexually active women, including vaginal odor, discharge, and discomfort associated with pH imbalance. Bacterial vaginosis, often triggered by pH disruption from semen, affects approximately 30% of women of reproductive age.
